Journal of Medicinal Chemistry · 2004 · 60 citations · 19 references
MedicineMedicinal ChemistryPharmacologyMolecular PharmacologyNeuropharmacologyStructure-activity RelationshipsDopaminergic PharmacologyDrug-receptor InteractionsLigand BindingReceptor PharmacologyReceptor-ligand InteractionsParkinson’s Disease PharmacotherapySelectivity
Piperazine derivatives of 2-furanyl[1,2,4]triazolo[1,5-a][1,3,5]triazine have recently been demonstrated to be potent and selective adenosine A(2a) receptor antagonists with oral activity in rodent models of Parkinson's disease. We have replaced the piperazinyl group with a variety of linear, monocyclic, and bicyclic diamines. Of these diamines, (R)-2-(aminomethyl)pyrrolidine is a particularly potent and selective replacement for the piperazinyl group. With this diamine component, we have been able to prepare numerous analogues with low nanomolar affinity toward the A(2a) receptor and good selectivity with respect to the A(1) receptor (>200-fold in some cases). Selected analogues from this series of [1,2,4]triazolo[1,5-a][1,3,5]triazine have now been shown to be orally active in the mouse catalepsy model.
19
The catalepsy test: Its ups and downs.
Paul R. Sanberg, Michael Bunsey, Magda Giòrdano et al. · Behavioral Neuroscience · 1988 · 321 citations
115th National Meeting American Chemical Society
Chemical & Engineering News · 1949 · 288 citations